Category: Finance
Rise and Shine: Everything you need to know before the ASX opens
Good morning everyone, and welcome to 11 April, 2024 – an important date in the history of military happenings for a variety of nations around [more…]
Monsters of Rock: One of the ASX’s best gold stocks runs down takeover target, tin miner goes parabolic
Perseus moves up to a ~75% stake in $270 million takeover target OreCorp Tin prices charged past US$30,000/t overnight, with three month prices on the [more…]
Closing Bell: Iron ore, health stocks out in front; gold explorer Forrestania doubles
ASX climbs further, buoyed by mining and health stocks RBNZ keeps its cash rate at 5.5pc despite recession US inflation print due later today, keeping [more…]
Lithium drilling poised to begin as CuFe lines up 3.5km of targets
A 3.5km-long lithium anomaly has been identified Heritage agreement signed and program of works approved for Stage 1 drilling of North Dam RC drilling to [more…]
Viva Energy taps DataMesh for next-gen payments and customer experience
Viva Energy and DataMesh forge transformative payment technology partnership Integration of DataMesh’s Unify across Viva’s network promises seamless transactions Collaboration targets future-proof, contactless, and digital [more…]
Long Shortz with Lithium Universe: Shooting for the stars and landing in North America
Stockhead’s Ashtyn Hiron sits down with Lithium Universe (ASX:LU7) CEO Alex Hanly to get the short end of the long story on the company’s latest [more…]
PharmAust inks approval from Macquarie University for Open-Label MND extension study
Macquarie University has given ethics approval to PharmAust allowing the final 3 patients to be enrolled in the Open-Label Extension study of monepantel The study [more…]
Maiden resource imminent after stellar metallurgy results as Felix looks to tap into record high gold market
Impressive recoveries averaged 89% from near surface oxide gold mineralisation, and reached as high as 94.5% An initial maiden JORC resource in progress right next [more…]
Neurotech hits new milestone in Phase II/III autism trial after treating last patient
Special Report: Neurotech has treated the last patient in its Phase II/III NTIASD2 clinical trial for children with Autism Spectrum Disorder. The trial, aiming to [more…]
ASX Small Caps Lunch Wrap: Who’s been baffled by the sun disappearing this week?
Local markets were up this morning, climbing around +0.45% early in the session and hanging in at that level as Wednesday dragged on – mostly thanks [more…]
